Why the study?
Despite decades of study, little consensus exists on risk factors, biomarkers, or management strategies following a 5FU-cardiotoxicity event in colorectal cancer.
How should 5FU-induced cardiotoxicity be managed and do alternative non-5FU regimens reduce the risk of recurrent cardiotoxicity in patients with colorectal cancer?
How should 5FU-induced cardiotoxicity be managed and do alternative non-5FU regimens reduce the risk of recurrent cardiotoxicity in patients with colorectal cancer?
Due to the high risk of recurrent cardiotoxicity upon 5FU rechallenge in colorectal cancer patients, utilizing alternative non-5FU regimens is a critical management strategy.
5FU-cardiotoxicity in CRC lacks consensus on risks and management; leaves open the need for prospective studies on biomarkers and care.
Fluorouracil (5FU) is the backbone chemotherapy agent in the treatment of colorectal cancer (CRC). Cardiotoxicity represents an uncommon but serious side effect of treatment with 5FU. Here, we review the current literature on 5FU-cardiotoxicity in the setting of CRC specifically, with a focus on data from the modern era of combination chemotherapy. Despite decades of study, there is little consensus on risk factors and biomarkers for 5FU-cardiotoxicity, nor how patients with CRC should be managed following a cardiotoxicity event. Given the elevated risk of recurrent cardiotoxicity on rechallenge, the use of alternative regimens that do not contain 5FU is a critical aspect of management. Data on the cardiotoxicity risk and efficacy of non-5FU regimens in CRC are therefore reviewed in detail.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: